Evidence map›Paper›PMID 41805718›Full record

ArticlePLoS pathogens2026

CD28-deficient mice are vulnerable to mouse papillomavirus MmuPV1 infection of the skin and mucosae.

Sarah Brendle, Jingwei Li, Song Lu, Todd D Schell, Michael Kozak, Vonn Walter, Debra Shearer, Joshua Place, Karla Balogh, Jean-Laurent Casanova and 6 more

Abstract read
In one paragraph

Article in PLoS pathogens, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Sarah BrendleJake Gittlen Laboratories for Cancer Research, Pennsylvania State University, Hershey, Pennsylvania, United States of America.
Jingwei LiJake Gittlen Laboratories for Cancer Research, Pennsylvania State University, Hershey, Pennsylvania, United States of America.
Song LuDepartment of Pathology and Laboratory Medicine, Pennsylvania State University, Hershey, Pennsylvania, United States of America.
Todd D SchellDepartment of Cell & Biological Systems, Pennsylvania State University, Hershey, Pennsylvania, United States of America.
Michael KozakJake Gittlen Laboratories for Cancer Research, Pennsylvania State University, Hershey, Pennsylvania, United States of America.
Vonn WalterDepartment of Public Health Sciences, Pennsylvania State University, Hershey, Pennsylvania, United States of America.
Debra ShearerJake Gittlen Laboratories for Cancer Research, Pennsylvania State University, Hershey, Pennsylvania, United States of America.
Joshua PlaceDepartment of Comparative Medicine, Pennsylvania State University, College of Medicine, Hershey, Pennsylvania, United States of America.
Karla BaloghJake Gittlen Laboratories for Cancer Research, Pennsylvania State University, Hershey, Pennsylvania, United States of America.
Jean-Laurent CasanovaLaboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM, Necker Hospital for Sick Children, Paris, France.
Neil ChristensenJake Gittlen Laboratories for Cancer Research, Pennsylvania State University, Hershey, Pennsylvania, United States of America.
Adam D BurgenerCenter for Global Health and Diseases, Department of Pathology, School of Medicine, Case Western Reserve University, Cleveland, Ohio, United States of America.
Thomas T MurookaDepartment of Immunology, University of Manitoba, Manitoba, Winnipeg, Canada.
Yusheng ZhuDepartment of Pathology and Laboratory Medicine, Pennsylvania State University, Hershey, Pennsylvania, United States of America.
Vivien BéziatLaboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM, Necker Hospital for Sick Children, Paris, France.
Jiafen HuJake Gittlen Laboratories for Cancer Research, Pennsylvania State University, Hershey, Pennsylvania, United States of America.ORCID https://orcid.org/0000-0001-8700-9937

Funding

A co-infection model for papillomavirus associated infections and cancersR21CA274265 · NCI · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI GILBERT, NICOLE MARIE, HU, JIAFEN · 2023 to 2024
$433k
Role of estrous cycle and contraceptives in anogenital papillomavirus infectionR21AI121822 · NIAID · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI CHRISTENSEN, NEIL D, HU, JIAFEN · 2016 to 2017
$425k
The role of bacterial vaginosis-associated bacteria in papillomavirus persistence and cancersR21CA271069 · NCI · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI HU, JIAFEN, MUROOKA, THOMAS T. · 2022 to 2023
$393k
NCI NIH HHS R21 CA271069NCI NIH HHS R21 CA274265NIAID NIH HHS R21 AI121822
6 · The paper itself

Abstract

CD28 is a co-stimulatory molecule expressed on the surface of T cells. To date, three individuals with germline CD28 deficiency have been reported to develop recalcitrant, HPV-driven warts: one exhibited persistent lesions, another experienced disease resolution, and the third developed a chronic "tree-man" phenotype. In mice, we confirmed that CD28-knockout (CD28ko) animals on the C57BL/6 (B6) background are susceptible to cutaneous infection with mouse papillomavirus (MmuPV1); however, their skin warts regressed spontaneously approximately five weeks post-infection. Furthermore, we demonstrate that CD28ko mice are vulnerable to MmuPV1 infection at HPV-relevant mucosal sites, including the most HPV prevalent sites: anogenital tract and oral cavity. Virions recovered from vaginal lavage were infectious but could be neutralized by the neutralizing monoclonal antibody MPV.A4. Viral clearance at mucosal sites was delayed in CD28ko mice, persisting for up to six weeks in the lower genital tract. Blocking the CD28 ligands CD80 and CD86 in B6 mice reproduced the CD28ko phenotype following MmuPV1 infection and markedly reduced CD28 expression, implicating the CD28-CD80/CD86 axis in delayed viral clearance. Infected CD28ko mice showed a reduction in both CD4+ and CD8+ T cell population in the spleen compared to infected B6 mice, but an increase in CD11c+/F4-80+ cells, particularly the plasmacytoid dendritic cell (pDCs, SiglecH⁺) subset. Additionally, CD28ko mice exhibited delayed recruitment of activated CD4+ T cells to infected tissues. Accumulation of MmuPV1 E6/90-99-specific, tetramer-positive CD8+ cytotoxic T lymphocytes (CTLs) was slower in CD28ko than in B6 mice; these CTLs remained FoxP3 negative but displayed reduced efficacy in both in vitro killing and antiviral cytokine assays. Adoptive transfer of CTLs from either B6 or CD28ko mice into MmuPV1-infected Rag1ko mice induced viral clearance at mucosal (oral) sites, whereas B6-derived CTLs achieved more complete regression of cutaneous (tail) lesions. Collectively, these findings indicate that CD28 deficiency delays but does not prevent the clearance of papillomavirus infections at both cutaneous and mucosal sites in mice.

Indexed as

CD28 AntigensMucous MembranePapillomaviridaePapillomavirus InfectionsAnimalsB7-1 AntigenFemaleMiceMice, Inbred C57BLMice, KnockoutSkinB7-1 AntigenCD28 Antigens

Identifiers

PMID41805718
PMCPMC12974793

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.